Merck & Company, Inc. vs Ultragenyx Pharmaceutical Inc. — Stock Comparison
Merck & Company, Inc. (MRK) and Ultragenyx Pharmaceutical Inc. (RARE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. clearly outscores Ultragenyx Pharmaceutical Inc. on Q·Score (7 vs 5.4 out of 10), led by Quality (7.7 vs 2.2) and Growth (6.2 vs 3.4). Ultragenyx Pharmaceutical Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for RARE (+89.7%) than for MRK (+13.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 19% return on equity and 14% profit margins.
Consensus analyst target of $52.05 is 90% above current price.
⚠ currently unprofitable (-91% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
MRK vs RARE: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Ultragenyx Pharmaceutical Inc. (RARE) at 5.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: MRK or RARE?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 3.4/10). Merck & Company, Inc. reports revenue growth (4.9% YoY) while Ultragenyx Pharmaceutical Inc. reports (-2.2% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is MRK or RARE more attractively valued?
Ultragenyx Pharmaceutical Inc. (RARE) scores higher on Valuation (9/10 vs 6.7/10). MRK trades at 11.9× P/E versus RARE at 28.4×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about MRK vs RARE?
There are 27 analysts covering MRK with a consensus price target of $129.74, and 19 analysts covering RARE with a consensus target of $52.05. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: MRK or RARE?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 2.2/10). Net profit margin: MRK at 13.6%, RARE at -90.9%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: MRK or RARE?
Merck & Company, Inc. (MRK) scores higher on Financial Health (7/10 vs 5.4/10). Market beta: MRK at 0.22, RARE at 0.38. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of MRK and RARE?
Merck & Company, Inc. (MRK) has a market capitalisation of $281.2B, while Ultragenyx Pharmaceutical Inc. (RARE) has a market cap of $2.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do MRK or RARE pay dividends?
MRK pays a dividend yield of 2.99%, while RARE does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →